Analyst Price Targets — MIRM
Latest News for MIRM
Vertex Pharmaceuticals has shown steady financial growth. Mirum Pharmaceuticals is getting closer to being profitable.
MIRM heads into Q1 earnings with Livmarli sales in focus after 69% year-over-year growth in 2025. Bile acid products broaden revenue momentum.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals already markets three therapies. The company plans to report four pivotal readouts from clinical studies over the next 18 months.
STOCKHOLM, SE / ACCESS Newswire / April 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX), today announced the appointment of Tiago Nunes, MD, PhD, as Chief Medical Officer (CMO), effective May 1, 2026. Tiago Nunes is an experienced clinical development leader, with significant expertise advancing rare disease therapeutics through regulatory approval and launch, having most recently…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MIRM.
U.S. House Trading
No House trades found for MIRM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.